Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

Author(s):

Raj Chovatiya, MD, PhDGeorge Han, MD, PhD

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis

Now Viewing

EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients

EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice

EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis

EP: 7.Speed of Itch Relief in Atopic Dermatitis

EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis

EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

Video content above is prompted by the following:

Please review oral JAK inhibitors that are FDA approved for atopic dermatitis (AD) (abrocitinib, upadacitinib).
Are there any differences in the mechanism of action of FDA-approved JAK inhibitors compared with conventional therapies that are important for prescribers to know?
Why is treatment with oral JAK inhibitors an attractive option for AD?
At what point during a patient’s treatment journey would you recommend use of JAK inhibitors?
How does disease severity affect your recommendation?
In which patients would you consider using a JAK inhibitor? Please describe characteristics of an ideal patient for oral JAK inhibitor.